You are viewing the site in preview mode

Skip to main content

Table 1 Clinical and hormonal characteristics of the patients with POI

From: Whole-exome sequencing in patients with premature ovarian insufficiency: early detection and early intervention

Case ID Age (Years) Menopause
age (Years)
BMI (kg/m2) Primary or
secondary amenorrhea
FSH (IU/L) LH (IU/L) E2 (pg/mL) Karyotype Ovary size
(right/ left, mm)
Follicle
POI-1 35 33 25.20 secondary 35.92 16.61 24 46,XX 21*16/22*18 Rare
POI-3 29 27 28.25 secondary 161.18 56.92 21 46,XX 18*11/16*11 Absent
POI-6 30 28 24.14 secondary 73.77 27.56 79 46,XX 19*11/18*12 Absent
POI-7 23 13 23.80 primary 127.54 39.5 34 46,XX 15*10/13*9 Absent
POI-8 25 15 25.71 primary 92.93 43.38 13 46,XX 10*6/11*5 Absent
POI-9 24 18 25.46 secondary 102.8 38.39  20 46,XX 18*9/21*8 Absent
POI-11 32 31 22.31 secondary 48.65 40.24 18 46,XX 19*12/17*15 Rare
POI-12 28 27 25.65 secondary 86.57 35.77 22 46,XX 16*11/15*9 Rare
POI-14 30 28 22.83 secondary 110.38 51.60 16 46,XX 17*14/16*10 Absent
POI-17 25 24 22.86 secondary 55.24 36.83 15 46,XX 20*14/21*17 Rare
POI-18 27 26 27.55 secondary 60.45 50.46 18 46,XX 18*10/17*8 Rare
POI-21 22 14 23.07 primary 107.28 38.55 24 46,XX 11*6/12*5 Absent
POI-23 26 25 25.81 secondary 38.50 24.69 15 46,XX 17*15/16*13 Rare
POI-24 16 13 24.31 primary 49.66 35.52 33 46,XX 10*5/11*4 Absent
  1. Abbreviation: FSH Follicle-stimulating hormone, LH Luteinizing hormone, E2 Estradiol